Enovis (ENOV) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Smith & Nephew SNATS (SNN) has outperformed Enovis (ENOV) over the past year, losing 23.7% versus a loss of 43.6%. Over five years, SNN leads with a -23.0% price change compared with -79.7% for ENOV. Smith & Nephew SNATS is the larger company by market cap ($11.40 billion vs $1.02 billion), about 11.2 times the size, while Enovis is growing revenue faster (+6.7% vs +6.1%).
On valuation, Enovis trades at a lower forward P/E (4.9x vs 11.3x for Smith & Nephew SNATS). Smith & Nephew SNATS pays a dividend yielding 1.46%, while Enovis does not currently pay one. Smith & Nephew SNATS converts more of its revenue into profit, with a net margin of 10.1% versus -52.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | SNN |
|---|---|---|
| Share price | $17.69 | $27.24 |
| Market cap | $1.02B | $11.40B |
| 1-day change | +1.49% | +1.04% |
| YTD return | -33.60% | -16.98% |
| 1-year return | -43.61% | -23.74% |
| 5-year return | -79.70% | -23.03% |
| P/E ratio (TTM) | — | 18.53 |
| Forward P/E | 4.93 | 11.30 |
| EPS (TTM) | $-19.23 | $1.47 |
| Dividend yield | 0.00% | 1.46% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $2.25B | $6.16B |
| Revenue growth (YoY) | +6.66% | +6.09% |
| Net income (latest FY) | $-1.18B | $625.00M |
| Gross margin | 59.84% | 68.01% |
| Operating margin | -50.01% | 12.88% |
| Net margin | -52.69% | 10.14% |
| 52-week high | $34.28 | $37.51 |
| 52-week low | $16.70 | $26.12 |
| Distance from 52-week high | -48.40% | -27.38% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +112.44% | +18.65% |
| Average volume | 1.46M | 1.64M |
| Shares outstanding | 57.67M | 418.52M |
| Employees | 7,802 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Smith & Nephew SNATS is about 11.2 times larger than Enovis by market value ($11.40B vs $1.02B).
- SNN has outperformed ENOV by 19.9 percentage points over the past year.
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.46% vs 0.00%).
- Smith & Nephew SNATS is more profitable, keeping 10.1 cents of every revenue dollar as net income versus -52.7 cents for Enovis.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
ENOV vs SNN FAQ
Which is bigger, Enovis or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.40B compared with $1.02B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or SNN?
SNN returned -23.74% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Enovis or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.46%, while Enovis does not currently pay a regular dividend.
Are Enovis and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.